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Time to perform 7 clearly pre-specified tasks was recorded by trained observers 
using a stopwatch. Time of day measurements for subject time in GP surgery and 
vaccination room as well as consumables usage was collected. Time for tasks before 
vaccination day was obtained from opinion. A total 123 processes were observed 
(approximately 20 by site, equally distributed across visits 1 to 4). Analyses were 
run by site and pooled across sites using a random intercept model. Published 
2014 PSSRU data were used to transfer HCP time into cost. Results: Mean HCP 
time for a vaccination process (including a mean 2.75 vaccine doses) was 9.5min 
(95% CI: 7.7-11.3); site range: 7.0-11.3min. Associated cost (90% practice nurse, 10% 
support staff) was £6.2; range: £4.7-£7.7. Mean time for a single oral and intramus-
cular vaccine administration was 1.0 and 0.4min, respectively. Mean time for a 
single vaccine reconstitution was 0.8min. Mean time in GP surgery was 23.9min 
(95% CI: 19.2-28.5), of which 8.4min in vaccination room (95% CI: 5.5-11.2). When 
including average supplies cost (£0.27), as well as an estimated 10.1 minutes per 
vaccination process prior to vaccination day (£5.5), total estimated cost per visit 
was £12.0. ConClusions: Paediatric vaccination requires substantial resources, 
including staff, facility, and parental time. Potential changes in the vaccination 
schedule would have an impact on associated time and cost and the vaccination 
unit’s capacity to managing subjects.
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objeCtives: To assess the clinical and cost-effectiveness of basal insulin regimens 
for adults with type 1 diabetes mellitus (T1DM), from the English National Health 
Service (NHS) perspective, and inform NICE recommendation regarding optimal 
choice of basal insulin. Methods: We considered seven daily insulin regimens: 
neutral protamine hagedorn (NPH) (once (od), twice (bid) and four-times daily 
(qid)), detemir (od and bid), glargine (od) and degludec (od). A systematic review of 
randomised controlled trials (RCTs) published in Medline, Embase and Cochrane 
databases to August 2014 was undertaken. Relative effectiveness was assessed 
using Bayesian network meta-analysis (NMA) undertaken in WinBUGs. Two out-
comes were analysed: change in haemoglobin A1c (HbA1c) and rate of severe/major 
hypoglycaemia. The cost-utility analysis (CUA) was undertaken using the IMS-CORE 
Diabetes Model (IMS-CDM), following NICE reference case (lifetime time horizon, 
3.5% discount rate for both costs and QALYs (quality-adjusted life-years), net 
monetary benefit (NMB) calculated using a threshold of £20,000 per QALY gained). 
Sensitivity analyses were performed; including changing insulin dose, discount rate 
and cost of hypoglycaemic events. Results: Twenty eight RCTs were included in 
the NMA. The mean change in HbA1c ranged from -0.48% (SE= 0.10) for detemir-(bid) 
to –0.01% (SE= 0.17) for NPH-(qid). Mean rate of severe/major hypoglycaemia ranged 
from 29 (95%CI: 0.00 to 39.76) to 35 (95%CI: 0.00 to 46.73) events/100 person-years. 
The CUA showed that detemir-(bid) had the highest mean QALY-gain (11.09) and 
NMB (£181,456) per patient. Insulin glargine-(od) ranked second. Insulin degludec-
(od) was the most costly, with the highest treatment cost (£7,169). The optimal 
choice was robust to all changes except when high doses of detemir-(bid) were 
assumed (> 30% increment compared to other regimens); where glargine-(od) ranked 
first. ConClusions: Insulin detemir administered twice daily was the optimal 
basal regimen for adults with T1DM from the English NHS perspective; providing 
the highest QALY gain and NMB among the regimens considered.
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objeCtives: The annual incidence of venous thromboembolic (VTE) disease in 
Europe is 183 per 100,000. If preventative measures are not taken one in three surgi-
cal patients can experience a VTE. This study estimated the cost-effectiveness of 
novel oral anticoagulants in two primary prevention populations; post hip (THR) 
and post knee (TKR) replacement surgery. Methods: For both TKR and THR popula-
tions, initial consequences (180 days) were modelled using a decision tree, followed 
by a Markov model for long term consequences. We evaluated cost-effectiveness of 
dabigatran, rivaroxaban and apixaban, compared with low molecular weight heparin 
(LMWH). Subjects that experienced a recurrent event were treated with apixaban 
and then received aspirin daily for the remainder of their lives. Model inputs dif-
fered between the two populations. Relative treatment efficacy and safety inputs 
came from network meta-analyses; other model inputs were based on a variety of 
evidence sources. Discounted (3.5%) health and benefits (QALYs) over a lifetime were 
estimated. Results: In the THR population rivaroxaban had the highest incremental 
net monetary benefit of £453 (£-485 to £1,312) versus LMWH at a willingness to pay at 
£20,000 per QALY. Dabigatran and apixaban had a negative incremental net monetary 
benefit; £-1,066 (£-12,127 to £3,191) and £-2,284 (£-11,017 to £2,085) respectively. The 
results of the TKR population followed a similar trend. Rivaroxaban had the highest 
were assumed to be $5 (Minimum-Maximum for Scenario Analysis [Min-Max SA]: 
2-10) and $1, respectively. Both costs and benefits were discounted at 3%. Results: 
Over 42 malaria endemic sub-Saharan countries, vaccination with RTS,S at DTP-
coverage was estimated to avert 7.8 (95%CI:4.2-10.6) and 9.3 (95%CI:4.9-12.7) million 
malaria episodes and 50,198 (95%CI:-7,759-108,565) and 63,114 (95%CI:12,218-
110,465) malaria deaths for a birth cohort vaccinated without and with a 4th dose, 
respectively. The overall incremental cost-effectiveness ratio was estimated to reach 
$232 (Min-Max SA:111-433) and $248 (Min-Max SA:119-462) per disability-adjusted 
life-years averted without and with 4th dose, respectively. ConClusions: The 
potential public health impact of implementing RTS,S in infants is estimated to be 
substantial and likely a cost-effective intervention referring to the WHO willingness-
to-pay threshold. However impact and cost-effectiveness of RTS,S would increase if 
malaria vaccination is given at a later age when a higher efficacy has been reported.
va2
cost-effectiveness analysis of QuadRivalent veRsus tRivalent 
influenza vaccination in geRmany — linking a dynamic 
tRansmission model with health and economic outcomes
Dolk FC1, Eichner M2, Welte R3, Anastassopoulou A3, Van Bellinghen L4, Poulsen Nautrup 
B5, Van Vlaenderen I4, Schmidt-Ott R6, Schwehm M7, Postma M1
1University of Groningen, Groningen, The Netherlands, 2Epimos GmbH, Dusslingen, Germany, 
3GSK, München, Germany, 4CHESS in Health, Ternat, Belgium, 5EAH-Consulting, Aachen, 
Germany, 6GSK, Wavre, Belgium, 7ExploSYS GmbH, Leinfelden-Echterdingen, Germany
objeCtives: Trivalent influenza vaccine (TIV) contains two Influenza A strains, 
but only one of the two B-lineages, resulting in frequent mismatches between vac-
cines and circulating B-lineages during seasonal epidemics. Quadrivalent influ-
enza vaccine (QIV) prevents such mismatches by including both B-lineages. The 
objective of our study was to estimate the cost-effectiveness (CE) of QIV versus TIV 
in Germany by coupling influenza incidence generated by a dynamic individual-
based simulation to health and economic outcomes. Methods: An individual-
based simulation tool (known in the literature as 4FLU) was refined to estimate 
the impact of TIV and QIV on clinical infection incidence per year and age over 20 
calendar years in Germany. Cases were subsequently linked to health and economic 
outcomes. Inputs were gathered from national databases and published literature. 
Vaccination rates reflect the current coverage in Germany; 2014 was used as the 
baseline year for costs. The productivity costs (societal perspective) were calculated 
according to the human capital approach. Costs and effects were discounted at 
3% and 1.5%, respectively. Univariate and probabilistic sensitivity analyses were 
performed. Results: Per 100,000 inhabitants, QIV prevents 6,803 more clinical 
influenza cases and 6.45 more deaths than TIV, accumulated in 20 years. From the 
societal perspective, QIV dominates TIV, with € 1,424,323 of cost savings and 152 
QALYs gained (98 QALYs by preventing clinical cases and 54 QALYs by avoiding 
premature mortality). These results are sensitive to changes in perspective, vacci-
nation coverage, vaccine prices, productivity cost approach and discount rates, yet 
favorable CE remains. ConClusions: Based on our analysis, QIV is expected to be 
cost-effective, or even cost-saving in Germany. Our results are in line with findings 
from other studies using dynamic models and for other settings.
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objeCtives: Vaccination is established as one of the most effective methods to 
prevent influenza and reduce the related social and economic burden. The objec-
tives of this study were to estimate the cost-effectiveness ratios of using the live 
attenuated influenza vaccine (LAIV), indicated for children aged 2 to 18 years, 
as well as evaluate the impact of herd immunity in the non-vaccinated popula-
tion. Methods: An adaptable and flexible dynamic transmission model, stratified 
by age, was used to simulate the impact of influenza infection, with a time horizon 
of 5 years. This study was conducted in a payer perspective and was adapted to 
the Portuguese setting, as all data related to demographics and costs belonged to 
Portuguese sources. Results: In the base case scenario, two different childhood 
vaccination policies were compared: use the trivalent influenza vaccine (TIV) cur-
rently in the market or use the LAIV, both for healthy children population. For 
the same number of vaccinated individuals, the LAIV achieved a reduction in the 
incidence of influenza and in the number of deaths due to influenza mostly among 
the elderly, when compared with the results obtained with TIV. The incremental 
cost-effectiveness ratios obtained were 7,448 and 8,527€ /QALY, for a vaccination 
coverage of 25 and 75%, respectively. The net monetary benefit obtained was posi-
tive. ConClusions: The results showed that the strategy for influenza vaccination 
using LAIV in children is cost-effective as it reduces the costs related to influenza 
infection and has a positive impact in the Portuguese healthcare from direct and 
indirect protection in the community.
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objeCtives: Few studies have estimated time and associated cost related to a pae-
diatric vaccination visit. Time and Motion (T&M) methodology is suitable to collect 
efficiency-related outcomes. The aim was to quantify active healthcare professional 
(HCP) time and associated costs of a single vaccination process administered in a 
paediatric population in the UK. Methods: Paediatric vaccination processes were 
observed in 6 General Practitioner (GP) surgeries across UK in children 2-14 months. 
